Psoriasis:
Indications for: SILIQ
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and unresponsive to other systemic therapies.
Adult Dosage:
Give by SC inj into thigh, abdomen (except for area around navel), outer area of upper arm; rotate inj sites. 210mg at Weeks 0, 1, and 2 followed by 210mg every 2 weeks. If adequate response not achieved after 12–16 weeks, consider discontinuing.
Children Dosage:
Not established.
SILIQ Contraindications:
Crohn’s disease.
Boxed Warning:
Suicidal ideation and behavior.
SILIQ Warnings/Precautions:
Risk of suicidal ideation and behavior. History of depression or suicidality. May increase risk of infections. Chronic or history of recurrent infection: consider the risks/benefits. If a serious infection develops or is not responding to standard therapy, monitor closely and discontinue until resolves. Evaluate for TB infection prior to initiating; monitor for active TB during and after therapy. Patients with active TB infection: do not initiate. History of latent or active TB; consider anti-TB therapy prior to initiation. Discontinue if Crohn’s disease develops. Pregnancy. Nursing mothers.
SILIQ Classification:
Interleukin-17A antagonist.
SILIQ Interactions:
Avoid concomitant live vaccines. Concomitant CYP450 substrates with a narrow therapeutic index (eg, warfarin, cyclosporine); monitor and consider adjusting dose.
Adverse Reactions:
Arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, inj site reactions, influenza, neutropenia, tinea infections.
Note:
Available only through a restricted program under a REMS called the SILIQ REMS Program. For more information, visit www.SILIQREMS.com or call (855) 511-6135.
REMS:
Generic Drug Availability:
NO
How Supplied:
Single-dose prefilled syringes—2
